Buy BMY: Growth Pipeline Is Now Carrying the Batting Order — Time a Tactical Swing Trade
Bristol-Myers Squibb's growth portfolio - led by pumitamig and other oncology assets - has reached a turning point where it meaningfully offsets legacy patent pressure. At roughly $55 a share and a $112B market cap, the stock trades at ~15x earnings with a 4.5% yield and $11.9B in free cash flow. I favor a swing trade long with an entry at $55.00, …